Accelrys Announces New Product Releases, Including Incorporation of Its Open Platform Technology to Enable Creation of Integrated, Best-of-Breed Solutions.

SAN DIEGO -- Today at its AccelrysWorld annual conference and user event, Accelrys, Inc. (NASDAQ:ACCL) announced its second product launch of 2005. Products in the launch will feature expanded deployment of Accelrys' open platform technology that enables the creation of integrated, best-of-breed software solutions for pharmaceutical, chemical and materials researchers.

"We aim to help our customers tackle their most difficult research challenges, and we realize that for many customers this means having a solution that integrates Accelrys software with tools they have built themselves or obtained from other software vendors," commented Accelrys' president and CEO Mark Emkjer. "By taking advantage of our open platform technology and continuing to integrate our own portfolio into comprehensive software suites, we can help our customers streamline their workflows and focus their time on research and development efforts."

In this launch, Accelrys unveils Discovery Studio (DS) 1.5, the latest version of its comprehensive, easy-to-use suite of life science modeling and simulation tools used by protein modelers, structural biologists and computational chemists for drug discovery and optimization. Open platform technology will power the underlying architecture in this upcoming release, thus enabling the sharing and re-use of information and workflows. Based on a service-oriented architecture (SOA), DS 1.5 will allow the integration of scientific components developed by Accelrys as well as other third-party software vendors, and components developed by customers themselves. With this release, a commercial-grade life science graphics visualizer -- DS Visualizer -- will also be made available for free to all users.

For computational and medicinal chemists, command-line access in the pharmacophore model building and 3D database searching program Catalyst 4.11 will enable integration into workflow programs or into tools they've built themselves. On the cheminformatics side, a workflow wizard in the chemistry-enabled spreadsheet Accord for Excel Desktop 6.1 will allow chemists, chemical engineers and medicinal chemists to submit compounds and reactions to predefined data analysis pipelines. Continued development of enterprise-level Accord tool kits will enable IT professionals, software developers and chemists to create applications tailored to meet their specific chemical information management needs.

In the area of materials modeling, the migration of functionality from the Cerius2 and Insight II legacy product suites into Materials Studio (MS) 4.0 will complete a breadth of tools for multi-scale modeling from the electronic to the atomistic to the mesoscale. MS 4.0 will now enable users, including chemists, chemical engineers, analytical chemists, materials scientists, polymer scientists and computational chemists, to solve a wide range of critical research problems in the areas of nanotechnology, catalysis, polymers and crystallization. Highlights will include a new Sorption module to study the interaction of molecular species in porous materials -- an essential feature for gas separations and the petrochemical industry -- and a new Reflex QPA module to quantify the relative amounts of different phases in a multi-phase sample based on powder diffraction patterns, a powerful method for analyzing compositions of organic and inorganic materials in the chemical and pharmaceutical industries. In addition, members of Accelrys' Nanotechnology Consortium will receive a customized version of MS 4.0 that will include new functionality developed in the Nanotechnology Consortium. This new functionality will include nanotube and nanocluster builders, GULP 3.0, as well as ONETEP, a state-of-the-art tool for linear-scaling calculations within density-functional theory to systems containing thousands of atoms.

Accelrys' flexible and open technologies available in these products enable customers who require advice in analyzing and assessing enterprise needs to turn to Accelrys' Solutions Consulting Group. The Accelrys Solutions Consulting Group can design and build customized, cross-functional enterprise solutions in environments that consist of heterogeneous database and computing servers from Accelrys and other suppliers.

More Information

For more information on this launch, including details on new science, expanded platform support, and new scientific initiatives in the simulation of polymers, see http://www.accelrys.com/info/launch/

About Accelrys

Accelrys, Inc. (NASDAQ:ACCL) is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers, for product design as well as drug discovery and development. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The company is headquartered in San Diego, California. For more information about Accelrys, visit its website at http://www.accelrys.com/.

All product and company names mentioned herein may be the trademarks of their respective owners.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements, including statements relating to the new software releases discussed in this press release, are subject to risks and uncertainties including, but not limited to, the risks that the software will not be successfully completed, developed or achieve market acceptance, demand relating to such software, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys claims the protection of the safe harbor for forward-looking statements contained in the Act and, disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.